Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7175MR)

This product GTTS-WQ7175MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL), Follicular lymphoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7175MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13909MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ15184MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ15477MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ10811MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ1926MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ3614MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ1111MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ12991MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW